Belite Bio (BLTE) closed at $193.61 on Sep 4, 2026, up 13.2% on the day. The stock is up 20.5% over the past month, up 35.1% over three months and up 21.0% year to date. It trades 3.2% below its 52-week high of $200.00 and 103.2% above its 52-week low of $95.29. The close sits above its 50-day moving average ($158.22) and above its 200-day moving average ($157.88).
Yes — the Sep 4, 2026 close of $193.61 is 22.6% above the 200-day average of $157.88.
BLTE closed 3.2% below its 52-week high of $200.00.
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
